Thirty years of heart failure by Beggs, Simon & Gardner, Roy
  
 
 
 
 
Beggs, S. and Gardner, R. (2018) Thirty years of heart failure. European Heart Journal, 
39(10), pp. 824-826. 
 
   
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/158844/  
      
 
 
 
 
 
 
Deposited on: 17 April 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Title 
‘Thirty years of heart failure’. Highlights from the 20th British Society for Heart Failure Annual 
Autumn Meeting (23-24 November 2017) 
 
Authors 
Name:  Dr Simon Beggs 
Position: Cardiology research fellow 
Institution: University of Glasgow 
Address: Room 208 
  Ground floor 
  BHF Glasgow Cardiovascular Research Centre 
  126 University Place  
  G12 8TA 
Tel:  [mobile: 07599262002 – not for distribution] 
Email:  simon.beggs@glasgow.ac.uk 
 
Name:  Prof. Roy Gardner 
Position: Professor of heart failure 
Institution: Golden Jubilee National Hospital 
Address:  
 
 
The British Society for Heart Failure 20th Annual Autumn Meeting - held on 23-24th 
November 2017 in London – gave a tip of the hat to the landmark 1987 CONSENSUS trial [1] 
in adopting as its theme ‘Three decades of heart failure’. Dr Simon Beggs and Professor Roy 
Gardner report some of the highlights from a meeting that delivered education and 
enjoyment in equal measure for the nearly 900 delegates. 
 
Thirty years of heart failure  
In keeping with the historically commemorative tone, Professor Theresa McDonagh (King’s 
College London) delivered a chronological overview of the development of natriuretic peptide 
biomarkers in heart failure, ‘from bench to bedside’. Following from the discovery of atrial 
natriuretic peptide (ANP) in 1981, brain natriuretic peptide (BNP) was subsequently located 
in porcine cerebrum, before its predominant source in humans was located in the 
myocardium. Early mechanistic studies noted the vasodilatory effects of BNP, and 
characterised its role as a ‘white knight’ antagonist of the renin-angiotensin-aldosterone 
system. The clinical utility of BNP and its cousin, NT-proBNP, were demonstrated in a series 
of landmark studies, confirming both their strong negative predictive value for excluding 
heart failure in patients with undifferentiated breathlessness in the acute [2] and chronic [3] 
settings, and their prognostic value [4]. 
 
Professor John Cleland (University of Glasgow) similarly led the audience on a tour de force 
journey through the development of cardiac resynchronisation therapy (CRT). Tracing a 
remarkable story back to 1935, he located this as the first documentation that conduction 
disorders caused ventricular dyssynchrony [5]. Pacing-induced dyssynchrony was described 
in the 1960s and 1970s,[6] with early experimental treatments for dyssynchrony attempted 
in the 1980s and early 1990s [7-9]. Published in 2001, the MUSTIC trial [10] was a key 
milestone, demonstrating in a single-blinded cross-over trial that randomisation to CRT 
improved 6-minute walk distance among patients with heart failure and reduced ejection 
fraction (HFrEF) who were in sinus rhythm. In 2005, the CARE-HF and COMPANION trials 
[11,12] reported on the effects of CRT (with or without a defibrillator in the case of the latter 
trial) in patients who had HFrEF, were in NYHA functional class III or IV, and had a QRS duration 
of at least 120ms. The stunning results were that CRT reduced mortality by ~40%, and 
improved symptoms, quality of life, systolic blood pressure and left ventricular (LV) function. 
Looking to the future, Professor Cleland forecast that the evolutionary development of CRT 
might derive from advances in such fields as quadripolar, multisite, leadless or His-bundle 
pacing. 
Fifty years on from the first cardiac transplant  
Performed on 3rd December 1967, the first human heart transplant was another notable 
anniversary celebrated at this meeting. Half a century on, Dr Jayan Parameshwar (Papworth 
Hospital, Cambridge) summarised who should be referred for heart transplantation today. In 
the absence of clear contraindications, triggers to prompt urgent inpatient referral for 
transplant assessment include: 
• Inotrope or intravenous diuretic dependency  
• Requirement for IABP to prevent secondary organ failure  
• Intractable ventricular arrhythmias with ventricular dysfunction.  
• Ventilation for pulmonary oedema  
In an outpatient population, transplant assessment should be considered for patients with 
recurrent heart failure admissions, the need to decrease or stop prognostic medications, 
rising or persistently elevated natriuretic peptide concentrations, and worsening right 
ventricular function or systolic pulmonary artery pressure (>50 mmHg) on echocardiography. 
Whilst history’s first heart transplant recipient lived for just eighteen days, half a century of 
incremental advances in transplant care means that, following transplantation, median life 
expectancy for recipients today is at least eleven years, and continuing to rise. 
Update session 
Leaving history behind, Professor Mark Petrie (University of Glasgow) led the audience 
through a cutting edge update on peripartum cardiomyopathy (PPCM). Encouragingly, 
mortality due to PPCM may be falling, with 6-month survival 96% or greater in recent series. 
Data on longer term mortality are more sparse, with 7-8 year mortality estimated at 7-16%. 
Myocardial recovery is common, with 53-72% having a left ventricular ejection fraction (LVEF) 
>50% at 12 months, and 83% experiencing at least some recovery in LV function by this stage. 
This is critical in planning for further pregnancies, because the risk of recurrent heart failure 
or death is significantly higher in women with persistently reduced LVEF [13]. The therapeutic 
approach to PPCM is predominantly one that balances the presumed benefits of conventional 
heart failure therapies against the potential harms to the foetus of these interventions. Whilst 
bromocriptine has long been held as a specific therapy for PPCM – this being mechanistically 
intuitive due to the apparent pathophysiological role of prolactin in PPCM – the evidence for 
its efficacy is limited [14,15]. However, recent data from the worldwide registry on PPCM 
reveal that thromboembolic events occur in 7% of women by the end of the first month, 
suggesting an important role for anticoagulation [16]. Professor Petrie signed off by 
reminding the audience that counselling PPCM survivors regarding both contraception and 
subsequent pregnancies is crucial to mitigate future risk. 
BSH Young Investigators’ Award and Philip Poole-Wilson Memorial Medal 
Triumphing over fierce competition, Mrs Nathalie Conrad (The George Institute for Global 
Health, Oxford) emerged as the winner of the 2017 BSH Young Investigators’ Award. Her 
research used linked medical records from primary and secondary care to analyse patterns in 
the incidence of heart failure within a population of four million people tracked from 2002 to 
2014 [17]. Over this period there were 93,074 incident diagnoses of heart failure, with this 
total approximating new cases of breast, prostate, lung and bowel malignancy combined. 
Notably, socio-economic analysis revealed that deprived individuals were 61% more likely to 
develop heart failure and the gap in age at first presentation by socio-economic status 
widened in later years. Mrs Conrad concluded that incident heart failure represents a growing 
burden to health services in absolute terms, but that recognition of the link between social 
inequality and age of incident diagnosis hints at potentially reversible factors that might be 
targeted in the future. 
Finally, Professor Karl Swedberg (University of Gothenburg; Imperial College, London) was the 
recipient of the Society’s prestigious Philip Poole-Wilson Memorial Medal. This award, 
bestowed biennially, was in recognition of his extraordinary career contribution to heart 
failure research. Stretching back from vital recent work demonstrating the role of 
angiotensin–neprilysin inhibition in heart failure, Professor Swedberg has been a key player 
in the development of many essential heart failure therapies, including beta-blockers,[18] 
ivabradine [19] and, aptly for this meeting, enalapril, as one of the primary investigators in 
the CONSENSUS trial. 
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